a Clinical and Translational Research Center , University at Buffalo, The State University of New York , Buffalo , NY , USA.
b Division of Infectious Diseases, Department of Medicine , University at Buffalo, The State University of New York , Buffalo , NY , USA.
Hum Vaccin Immunother. 2017 Oct 3;13(10):2322-2331. doi: 10.1080/21645515.2017.1356951.
Moraxella catarrhalis is a major cause of morbidity and mortality worldwide, especially causing otitis media in young children and exacerbations of chronic obstructive pulmonary disease in adults. This pathogen uses several virulence mechanisms to colonize and survive in its host, including adherence and invasion of host cells, formation of polymicrobial biofilms with other bacterial pathogens, and production of β-lactamase. Given the global impact of otitis media and COPD, an effective vaccine to prevent M. catarrhalis infection would have a huge impact on the quality of life in both patient populations by preventing disease, thus reducing morbidity and health care costs. A number of promising vaccine antigens have been identified for M. catarrhalis. The development of improved animal models of M. catarrhalis disease and identification of a correlate of protection are needed to accelerate vaccine development. This review will discuss the current state of M. catarrhalis vaccine development, and the challenges that must be addressed to succeed.
卡他莫拉菌是全球发病率和死亡率的主要原因，尤其会导致婴幼儿中耳炎和成年人慢性阻塞性肺疾病恶化。这种病原体使用几种毒力机制在其宿主中定植和存活，包括黏附和侵袭宿主细胞、与其他细菌病原体形成多微生物生物膜，以及产生β-内酰胺酶。鉴于中耳炎和 COPD 的全球影响，预防 M. catarrhalis 感染的有效疫苗将通过预防疾病对这两个患者群体的生活质量产生巨大影响，从而降低发病率和医疗保健成本。已经确定了许多有希望的 M. catarrhalis 疫苗抗原。需要开发改进的 M. catarrhalis 疾病动物模型并确定保护相关性，以加速疫苗开发。这篇综述将讨论 M. catarrhalis 疫苗开发的现状，以及为取得成功必须解决的挑战。
